PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway

Although preclinical work with rapalogs suggests potential in the treatment of gastric cancer, they have been less successful clinically. In this study, we report the impact of the investigational drug PP242, a potent and selective small-molecule active-site TORC1/2 kinase inhibitor, on tumor growth and metastasis. The antiproliferative effect of PP242 was assessed using the Cell Counting Kit-8 assay. The migration and invasion potential were analyzed using wound-healing and transwell assays, respectively. The Matrigel capillary tube formation assay was performed to mimic in-vivo angiogenesis. Immunoblotting and immunofluorescence were used to observe protein levels and distribution of actin fibers. Finally, S2448p-mammalian target of rapamycin (mTOR) expression was detected on gastric cancer tissues using immunohistochemistry. First, PP242 potently inhibited cell proliferation in gastric cancer cell lines and in human endothelial cells in vitro at the IC50 ranged from 50 to 500 nmol/l. Then, an inhibitory effect of PP242 on metastasis was observed in gastric cancer cell AGS, along with the cytoskeletal rearrangements and suppression of the phosphorylation of PI3K downstream factors including AKT, mTOR, and P70S6K. Furthermore, PP242 was found to decrease the tube formation and migration of human umbilical vein endothelial cells. Using immunohistochemistry, we found that S2448p-mTOR staining was observed in 41.8% (82/196) of gastric cancer tissues and correlated with depth of mural invasion, lymph node metastasis, tumor node metastasis stage, and vascular invasion. These results show that PP242 suppresses cell proliferation and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway, which might be an effective novel therapeutic candidate against gastric cancer in the future.

[1]  N. Dubey,et al.  Congenital Triangular Alopecia: The 127th Case , 2016, International journal of trichology.

[2]  Sang Gyun Kim,et al.  Rapamycin: one drug, many effects. , 2014, Cell metabolism.

[3]  D. Hansel,et al.  Mammalian Target of Rapamycin Complex 2 (mTORC2) Is a Critical Determinant of Bladder Cancer Invasion , 2013, PloS one.

[4]  H. Nam,et al.  Rapamycin inhibits both motility through down-regulation of p-STAT3 (S727) by disrupting the mTORC2 assembly and peritoneal dissemination in sarcomatoid cholangiocarcinoma , 2013, Clinical & Experimental Metastasis.

[5]  J. Ji,et al.  Therapeutic implications of mTOR inhibitors in the treatment of gastric cancer. , 2013, Current cancer drug targets.

[6]  G. Sledge,et al.  Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models , 2012, Breast Cancer Research and Treatment.

[7]  N. Demartines,et al.  Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells , 2012, BMC Cancer.

[8]  Nicholas T. Ingolia,et al.  The translational landscape of mTOR signalling steers cancer initiation and metastasis , 2012, Nature.

[9]  R. Schneider,et al.  Targeting the mTOR/4E-BP Pathway in Endometrial Cancer , 2011, Clinical Cancer Research.

[10]  J. Sanders,et al.  The physiology and pathophysiology of rapamycin resistance , 2011, Cell cycle.

[11]  D. Sabatini,et al.  mTOR: from growth signal integration to cancer, diabetes and ageing , 2010, Nature Reviews Molecular Cell Biology.

[12]  F. Penault-Llorca,et al.  [HER2 and gastric cancer: a novel therapeutic target for trastuzumab]. , 2010, Bulletin du cancer.

[13]  J. Gera,et al.  Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. , 2010, Blood.

[14]  K. Baggerly,et al.  Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. , 2010, Blood.

[15]  D. Guertin,et al.  Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy , 2010, Oncogene.

[16]  H. Azim,et al.  Targeting mTOR in cancer: renal cell is just a beginning , 2010, Targeted Oncology.

[17]  R. Abraham,et al.  Targeting mTOR globally in cancer: Thinking beyond rapamycin , 2009, Cell cycle.

[18]  D. Sabatini,et al.  mTOR Mediated Anti-Cancer Drug Discovery. , 2009, Drug discovery today. Therapeutic strategies.

[19]  Funda Meric-Bernstam,et al.  Targeting the mTOR signaling network for cancer therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Qiang Li,et al.  Overexpression of Phosphorylated Mammalian Target of Rapamycin Predicts Lymph Node Metastasis and Prognosis of Chinese Patients with Gastric Cancer , 2009, Clinical Cancer Research.

[21]  E. Berns,et al.  The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer , 2009, British Journal of Cancer.

[22]  K. Kojima,et al.  Relation between outcomes and localisation of p-mTOR expression in gastric cancer , 2009, British Journal of Cancer.

[23]  H. Lane,et al.  AKT/mTOR Pathway Activation and BCL-2 Family Proteins Modulate the Sensitivity of Human Small Cell Lung Cancer Cells to RAD001 , 2009, Clinical Cancer Research.

[24]  J. Blenis,et al.  Not all substrates are treated equally: Implications for mTOR, rapamycin-resistance, and cancer therapy , 2009, Cell cycle.

[25]  S. Marastoni,et al.  mTOR pathway and mTOR inhibitors as agents for cancer therapy. , 2008, Current cancer drug targets.

[26]  B. Wouters,et al.  Hypoxia signalling through mTOR and the unfolded protein response in cancer , 2008, Nature Reviews Cancer.

[27]  J. Cicenas.  The potential role of Akt phosphorylation in human cancers. , 2008, The International journal of biological markers.

[28]  S. Saito,et al.  Blocking on the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells. , 2008, European journal of cancer.

[29]  P. Houghton,et al.  mTOR and cancer therapy , 2006, Oncogene.

[30]  Robert R. Klein,et al.  Expression of mTOR signaling pathway markers in prostate cancer progression , 2006, The Prostate.

[31]  R. Loewith,et al.  Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive , 2004, Nature Cell Biology.

[32]  P. Diest,et al.  The Breast. , 2000 .

[33]  E. Fearon,et al.  Cancer progression , 1999, Current Biology.

[34]  M. Karsy,et al.  Deciphering the signaling pathways of cancer stem cells of glioblastoma multiforme: role of Akt/mTOR and MAPK pathways. , 2011, Advances in enzyme regulation.

[35]  M. Hidalgo,et al.  Targeting mTOR for cancer treatment. , 2006, Current opinion in investigational drugs.

[36]  J. Higginson.  International agency for research on cancer. , 1974, Archives of pathology.